search
Back to results

Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab

Primary Purpose

Atopic Dermatitis

Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Placebo
ASLAN004
Sponsored by
ASLAN Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Atopic Dermatitis focused on measuring atopic dermatitis, IL-13, ASLAN004, IL-13Rα1, Eczema, Anti-IL-13Rα1, atopic eczema

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male or female participants ≥18 years Willing and able to comply with clinic visits and study-related procedures Chronic AD present for at least 1 year prior to screening Have vIGA score of ≥3 (scale of 1 to 4) at baseline Have ≥10% BSA of AD involvement at baseline Have EASI ≥16 at screening and baseline History of inadequate response to, intolerance to or contraindication to a stable regimen of topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) as treatment for AD All participants must have previously been treated with dupilumab meeting one of the following conditions: Participants who stopped dupilumab treatment due to non-response, partial response, loss of efficacy must have been previously treated with dupilumab for at least 16 weeks duration; Participants who stopped dupilumab treatment due to intolerance or adverse events (AEs) to the drug may enter the study with no required prior length of dupilumab treatment; Participants who stopped dupilumab treatment due to cost or loss of access to dupilumab or for any other reasons may enter the study with no required prior length of dupilumab treatment; Exclusion Criteria: Use of immunosuppressive/immunomodulating drugs and/or therapies, JAK inhibitors, or phototherapy (including tanning booth/parlor) within 4 weeks prior to the Baseline visit Have an uncontrolled chronic disease that may require multiple intermittent use of systemic corticosteroids at Screening, as defined by the Investigator Have uncontrolled asthma that might require bursts of oral or systemic corticosteroids, or require either of the following due to ≥1 exacerbations within 12 months before Baseline: Systemic (oral and/or parenteral) corticosteroid treatment; Hospitalization for >24 hours; Have had systemic treatment with small molecule investigational drugs within 8 weeks or 5 half-lives (if known), whichever is longer, prior to the Baseline visit Have received treatment with topical corticosteroids (TCS), topical calcineurin inhibitors (TCI) such as tacrolimus and pimecrolimus, topical phosphodiesterase inhibitors such as crisaborole, topical JAK inhibitors (commercial or investigational use), within 1 week prior to randomization Have inadequate organ function or abnormal lab results considered clinically significant by the Investigator at the Screening visit History of human immunodeficiency virus (HIV) or positive HIV serology at Screening Infected with hepatitis B or hepatitis C viruses. For Hepatitis B, all subjects will undergo testing for Hepatitis B Surface Antigen (HBsAg) and Hepatitis B Core Antibody (HBcAb) during Screening. Subjects who are HBsAg positive are not eligible for the study. Subjects who are HBsAg negative and HBcAb positive will be tested for Hepatitis B Surface Antibody (HBsAb) and if HBsAb is positive, may be enrolled in the study; if HBsAb is negative, the subject is not eligible for the study. For Hepatitis C, all subjects will undergo testing for Hepatitis C antibody (HCVAb) during Screening. Subjects who are HCVAb positive are not eligible for the study. Active COVID-19 infection at Baseline. Have known liver cirrhosis and/or chronic hepatitis of any etiology Known diagnosis of active tuberculosis or non-tuberculous mycobacterial infection or latent tuberculosis unless it is well documented by a specialist that the patient has been adequately treated Allergen immunotherapy should be discontinued 6 months before randomization

Sites / Locations

  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting
  • ASLAN Investigative SiteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Placebo

ASLAN004

Arm Description

Placebo loading dose equivalents at Baseline and Week 1, then placebo dose equivalents every 2 weeks (q2w) from Week 2 to Week 14

Week 0, 1: LD of 600 mg; Week 2 through Week 15 QW: 400 mg dose

Outcomes

Primary Outcome Measures

Percent change from Baseline in Eczema Area and Severity Index (EASI) at Week 16
The EASI score is used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD

Secondary Outcome Measures

Proportion of participants achieving validated Investigator's Global Assessment (vIGA) response of 0 (clear) or 1 (almost clear) at Week 16
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear)
Proportion of participants with a 75% reduction Eczema Area and Severity Index 75 (EASI)
EASI scores range from 0 to 72 (severe)The EASI responder is defined as a participant who achieves a ≥75% improvement (EASI 75) from baseline in the EASI score
Proportion of participants achieving EASI 50
EASI scores range from 0 to 72 (severe)The EASI responder is defined as a participant who achieves a ≥50% improvement (EASI 50) from baseline in the EASI score
Proportion of participants achieving EASI 90
EASI scores range from 0 to 72 (severe)The EASI responder is defined as a participant who achieves a ≥90% improvement (EASI 90) from baseline in the EASI score
Proportion of participants with EASI <7
EASI scores range from 0 to 72 (severe)
Absolute and percent change in peak Pruritus Numerical Rating Scale (P-NRS)
The P-NRS is an 11-point scale used by patients to assess their worst itch severity over the past 24 hours, with 0 indicating no itch and 10 indicating the worst itch imaginable. Pruritus assessments will be recorded daily by the patient using an electronic diary
Proportion of participants achieving a 4-point reduction in peak Pruritus Numerical Rating Scale
Pruritus Numerical Rating Scale
Change in Body Surface Area (BSA) affected with AD
BSA ranges from 0% to 100 % with higher values representing greater extent of AD
Change in SCORing Atopic Dermatitis (SCORAD)
The SCORAD is a validated measure of the extent and severity of atopic dermatitis lesions, along with subjective symptoms. The score ranges from 0 to 103, with higher values indicating a more extensive and/or severe condition
Change in Dermatology Life Quality Index (DLQI)
The DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the patient's perception of the impact of AD disease symptoms and treatment on their quality of life (QoL). The 10 questions assess QoL over the past week, with an overall scoring of 0 (absent disease) to 30 (severe disease). A high score is indicative of a poor QoL
Change in Patient-Oriented Eczema Measure (POEM)
The POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor QoL)
Change in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Index Score United States and United Kingdom Algorithm
The EQ-5D-5L is a 2-part measurement. The second part is assessed using a visual analog scale (VAS) that ranges from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine
Absolute and percent change in sleep disturbance numerical rating scale (SD-NRS)
The SD-NRS is an 11-point scale used by patients to assess their sleep disturbance severity over the past 24 hours, with 0 indicating no or minimal sleep disturbance and 10 indicating the worst imaginable sleep disturbance. SD-NRS assessments will be recorded daily by the patient using an electronic diary
Proportion of participants achieving a 4-point reduction in sleep disturbance numerical rating scale
Percent change from baseline of validated Investigator's Global Assessment (vIGA)
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear)
Percent change from baseline of Eczema Area and Severity Index
EASI scores range from 0 to 72 (severe)
Number of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) from study drug administration

Full Information

First Posted
January 9, 2023
Last Updated
May 18, 2023
Sponsor
ASLAN Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT05694884
Brief Title
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
Official Title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 21, 2022 (Actual)
Primary Completion Date
December 16, 2023 (Anticipated)
Study Completion Date
December 16, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ASLAN Pharmaceuticals

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atopic Dermatitis
Keywords
atopic dermatitis, IL-13, ASLAN004, IL-13Rα1, Eczema, Anti-IL-13Rα1, atopic eczema

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
75 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo loading dose equivalents at Baseline and Week 1, then placebo dose equivalents every 2 weeks (q2w) from Week 2 to Week 14
Arm Title
ASLAN004
Arm Type
Experimental
Arm Description
Week 0, 1: LD of 600 mg; Week 2 through Week 15 QW: 400 mg dose
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
ASLAN004
Intervention Description
ASLAN004
Primary Outcome Measure Information:
Title
Percent change from Baseline in Eczema Area and Severity Index (EASI) at Week 16
Description
The EASI score is used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD
Time Frame
Baseline, Week 16
Secondary Outcome Measure Information:
Title
Proportion of participants achieving validated Investigator's Global Assessment (vIGA) response of 0 (clear) or 1 (almost clear) at Week 16
Description
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear)
Time Frame
Week 16
Title
Proportion of participants with a 75% reduction Eczema Area and Severity Index 75 (EASI)
Description
EASI scores range from 0 to 72 (severe)The EASI responder is defined as a participant who achieves a ≥75% improvement (EASI 75) from baseline in the EASI score
Time Frame
Week 16
Title
Proportion of participants achieving EASI 50
Description
EASI scores range from 0 to 72 (severe)The EASI responder is defined as a participant who achieves a ≥50% improvement (EASI 50) from baseline in the EASI score
Time Frame
Week 16
Title
Proportion of participants achieving EASI 90
Description
EASI scores range from 0 to 72 (severe)The EASI responder is defined as a participant who achieves a ≥90% improvement (EASI 90) from baseline in the EASI score
Time Frame
Week 16
Title
Proportion of participants with EASI <7
Description
EASI scores range from 0 to 72 (severe)
Time Frame
Week 16
Title
Absolute and percent change in peak Pruritus Numerical Rating Scale (P-NRS)
Description
The P-NRS is an 11-point scale used by patients to assess their worst itch severity over the past 24 hours, with 0 indicating no itch and 10 indicating the worst itch imaginable. Pruritus assessments will be recorded daily by the patient using an electronic diary
Time Frame
Week 16 and Week 24
Title
Proportion of participants achieving a 4-point reduction in peak Pruritus Numerical Rating Scale
Description
Pruritus Numerical Rating Scale
Time Frame
Week 16
Title
Change in Body Surface Area (BSA) affected with AD
Description
BSA ranges from 0% to 100 % with higher values representing greater extent of AD
Time Frame
Week 16 and Week 24
Title
Change in SCORing Atopic Dermatitis (SCORAD)
Description
The SCORAD is a validated measure of the extent and severity of atopic dermatitis lesions, along with subjective symptoms. The score ranges from 0 to 103, with higher values indicating a more extensive and/or severe condition
Time Frame
Week 16 and Week 24
Title
Change in Dermatology Life Quality Index (DLQI)
Description
The DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the patient's perception of the impact of AD disease symptoms and treatment on their quality of life (QoL). The 10 questions assess QoL over the past week, with an overall scoring of 0 (absent disease) to 30 (severe disease). A high score is indicative of a poor QoL
Time Frame
Week 16 and Week 24
Title
Change in Patient-Oriented Eczema Measure (POEM)
Description
The POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor QoL)
Time Frame
Week 16 and Week 24
Title
Change in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Index Score United States and United Kingdom Algorithm
Description
The EQ-5D-5L is a 2-part measurement. The second part is assessed using a visual analog scale (VAS) that ranges from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine
Time Frame
Week 16 and Week 24
Title
Absolute and percent change in sleep disturbance numerical rating scale (SD-NRS)
Description
The SD-NRS is an 11-point scale used by patients to assess their sleep disturbance severity over the past 24 hours, with 0 indicating no or minimal sleep disturbance and 10 indicating the worst imaginable sleep disturbance. SD-NRS assessments will be recorded daily by the patient using an electronic diary
Time Frame
Week 16 and Week 24
Title
Proportion of participants achieving a 4-point reduction in sleep disturbance numerical rating scale
Time Frame
Week 16
Title
Percent change from baseline of validated Investigator's Global Assessment (vIGA)
Description
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear)
Time Frame
Week 24
Title
Percent change from baseline of Eczema Area and Severity Index
Description
EASI scores range from 0 to 72 (severe)
Time Frame
Week 24
Title
Number of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) from study drug administration
Time Frame
Week 24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female participants ≥18 years Willing and able to comply with clinic visits and study-related procedures Chronic AD present for at least 1 year prior to screening Have vIGA score of ≥3 (scale of 1 to 4) at baseline Have ≥10% BSA of AD involvement at baseline Have EASI ≥16 at screening and baseline History of inadequate response to, intolerance to or contraindication to a stable regimen of topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) as treatment for AD All participants must have previously been treated with dupilumab meeting one of the following conditions: Participants who stopped dupilumab treatment due to non-response, partial response, loss of efficacy must have been previously treated with dupilumab for at least 16 weeks duration; Participants who stopped dupilumab treatment due to intolerance or adverse events (AEs) to the drug may enter the study with no required prior length of dupilumab treatment; Participants who stopped dupilumab treatment due to cost or loss of access to dupilumab or for any other reasons may enter the study with no required prior length of dupilumab treatment; Exclusion Criteria: Use of immunosuppressive/immunomodulating drugs and/or therapies, JAK inhibitors, or phototherapy (including tanning booth/parlor) within 4 weeks prior to the Baseline visit Have an uncontrolled chronic disease that may require multiple intermittent use of systemic corticosteroids at Screening, as defined by the Investigator Have uncontrolled asthma that might require bursts of oral or systemic corticosteroids, or require either of the following due to ≥1 exacerbations within 12 months before Baseline: Systemic (oral and/or parenteral) corticosteroid treatment; Hospitalization for >24 hours; Have had systemic treatment with small molecule investigational drugs within 8 weeks or 5 half-lives (if known), whichever is longer, prior to the Baseline visit Have received treatment with topical corticosteroids (TCS), topical calcineurin inhibitors (TCI) such as tacrolimus and pimecrolimus, topical phosphodiesterase inhibitors such as crisaborole, topical JAK inhibitors (commercial or investigational use), within 1 week prior to randomization Have inadequate organ function or abnormal lab results considered clinically significant by the Investigator at the Screening visit History of human immunodeficiency virus (HIV) or positive HIV serology at Screening Infected with hepatitis B or hepatitis C viruses. For Hepatitis B, all subjects will undergo testing for Hepatitis B Surface Antigen (HBsAg) and Hepatitis B Core Antibody (HBcAb) during Screening. Subjects who are HBsAg positive are not eligible for the study. Subjects who are HBsAg negative and HBcAb positive will be tested for Hepatitis B Surface Antibody (HBsAb) and if HBsAb is positive, may be enrolled in the study; if HBsAb is negative, the subject is not eligible for the study. For Hepatitis C, all subjects will undergo testing for Hepatitis C antibody (HCVAb) during Screening. Subjects who are HCVAb positive are not eligible for the study. Active COVID-19 infection at Baseline. Have known liver cirrhosis and/or chronic hepatitis of any etiology Known diagnosis of active tuberculosis or non-tuberculous mycobacterial infection or latent tuberculosis unless it is well documented by a specialist that the patient has been adequately treated Allergen immunotherapy should be discontinued 6 months before randomization
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
ASLAN Pharmaceuticals
Phone
+6562224235
Email
contact@aslanpharma.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chief Medical Officer
Organizational Affiliation
ASLAN Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
ASLAN Investigative Site
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35244
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Encino
State/Province
California
ZIP/Postal Code
91436
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Fountain Valley
State/Province
California
ZIP/Postal Code
92708
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90025
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Boca Raton
State/Province
Florida
ZIP/Postal Code
33486
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33021
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33436
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Miami Lakes
State/Province
Florida
ZIP/Postal Code
33014
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
North Miami Beach
State/Province
Florida
ZIP/Postal Code
33162
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Orange City
State/Province
Florida
ZIP/Postal Code
32720
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32819
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Saint Augustine
State/Province
Florida
ZIP/Postal Code
32080
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
33705
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Tampa
State/Province
Florida
ZIP/Postal Code
33607
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Columbus
State/Province
Georgia
ZIP/Postal Code
31904
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40217
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Quincy
State/Province
Massachusetts
ZIP/Postal Code
02169
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Auburn Hills
State/Province
Michigan
ZIP/Postal Code
48326
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89148
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73118
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73120
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Johnston
State/Province
Rhode Island
ZIP/Postal Code
02919
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29407
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Rapid City
State/Province
South Dakota
ZIP/Postal Code
57702
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37215
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Webster
State/Province
Texas
ZIP/Postal Code
77598
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Mill Creek
State/Province
Washington
ZIP/Postal Code
98102
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
contact@aslanpharma.com
Facility Name
ASLAN Investigative Site
City
Toronto
State/Province
Ontario
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
M5A3R6
Email
contact@aslanpharma.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab

We'll reach out to this number within 24 hrs